Intense Androgen-Deprivation Therapy With Abiraterone Acetate Plus Leuprolide Acetate in Patients With Localized High-Risk Prostate Cancer: Results of a Randomized Phase II Neoadjuvant Study
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Intense Androgen-Deprivation Therapy With Abiraterone Acetate Plus Leuprolide Acetate in Patients With Localized High-Risk Prostate Cancer: Results of a Randomized Phase II Neoadjuvant Study
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume 32, Issue 33, Pages 3705-3715
Publisher
American Society of Clinical Oncology (ASCO)
Online
2014-10-14
DOI
10.1200/jco.2013.53.4578
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeted Androgen Pathway Suppression in Localized Prostate Cancer: A Pilot Study
- (2013) Elahe A. Mostaghel et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer
- (2012) Robert W. Ross et al. CANCER
- Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
- (2012) Karim Fizazi et al. LANCET ONCOLOGY
- Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
- (2012) Charles J. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Expression of SLCO Transport Genes in Castration-Resistant Prostate Cancer and Impact of Genetic Variation in SLCO1B3 and SLCO2B1 on Prostate Cancer Outcomes
- (2011) J. L. Wright et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Clinical and Biochemical Consequences of CYP17A1 Inhibition with Abiraterone Given with and without Exogenous Glucocorticoids in Castrate Men with Advanced Prostate Cancer
- (2011) Gerhardt Attard et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- SLCO2B1 and SLCO1B3 May Determine Time to Progression for Patients Receiving Androgen Deprivation Therapy for Prostate Cancer
- (2011) Ming Yang et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
- (2011) Luca Gianni et al. LANCET ONCOLOGY
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dihydrotestosterone Administration Does Not Increase Intraprostatic Androgen Concentrations or Alter Prostate Androgen Action in Healthy Men: A Randomized-Controlled Trial
- (2010) Stephanie T. Page et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Novel secondary hormonal therapy in advanced prostate cancer: an update
- (2009) Eliezer M Van Allen et al. CURRENT OPINION IN UROLOGY
- From pathogenesis to prevention of castration resistant prostate cancer
- (2009) Helmut Bonkhoff et al. PROSTATE
- Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth
- (2008) R. B. Montgomery et al. CANCER RESEARCH
- Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven
- (2008) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- The face of high risk prostate cancer
- (2008) Peter C. Albertsen WORLD JOURNAL OF UROLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started